

Morbus Fabry Eine interdisziplinäre Herausforderung

M. Cybulla H. P. H. Neumann

aus BDI aktuell 1/2008

- 1** Anderson W. A case of „angio-keratoma“. Br J Dermatol 1898; 10: 113-117
- 2** Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIb study. J Inher Metab Dis 2003; 26: 617-627
- 3** Banikazemi M, Bultas J, Waldek S. et al. Agalsidase-beta therapy for advanced Fabry disease. Ann Intern Med 2007; 146: 77-86
- 4** Beck M, Ries M. Morbus Fabry - Clinical manifestation, diagnosis and therapy. OCC Europe Ltd London 2002
- 5** Beck M, Ricci R, Widmer U. et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004; 34: 838-844
- 6** Becker AE, Schooli R, Balk AG, van der Heide RM. Cardiac manifestations of Fabry's disease. Report of a case with mitral insufficiency and electrocardiographic evidence of myocardial infarction. Am J Cardiol 1975; 36: 829-835
- 7** Bekri S, Lidove O, Jaussaud R, Knebelmann B, Barbey F. The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of fabry disease: a review of the literature. Cardiovasc Hematol Agents Med Chem 2006; 4: 289-297
- 8** Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 2006; 69: 1216-1221
- 9** Cybulla M, Schaefer E, Wendt S. et al. Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys. Am J Kidney Dis 2005; 45: e82-89
- 10** Cybulla M, Walter k, Neumann HPH. et al. Morbus Fabry: Demographische Übersicht seit Einführung der Enzymersatztherapie. Dtsch Med Wochenschr 2007, p. 1505-1509
- 11** Desnick RJIY, Eng CM. alpha-Galactosidase A deficiency: Fabry disease. 7th ed. McGraw-Hill, Inc New York 1995
- 12** Desnick RJ, Wasserstein MP. Fabry disease: clinical features and recent advances in enzyme replacement therapy. Adv Nephrol Necker Hosp 2001; 31: 317-339
- 13** Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr 2004; 144: 5 Suppl S20-26
- 14** Elliott PM, Kindler H, Shah JS. et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 2006; 92: 357-360
- 15** Eng CM, Guffon N, Wilcox WR. et al. Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16
- 16** Eng CM, Banikazemi M, Gordan RE. et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substarte clearance, and safety studies. Am J Hum Genet 2001; 68: 711-722
- 17** Fabry J. Ein Beitrag Zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa hemorrhagica Hebrae). Arch Derm Syph 1898; 43: 187-200
- 18** Fachinformation Replagal. November 2006
- 19** Fachinformation Fabrazyme. August 2006
- 20** Fellgiebel A, Muller MJ, Mazanek M, Baron K, Beck M, Stoeter P. White matter lesion severity in male and female patients with Fabry disease. Neurology 2005; 65: 600-602
- 21** Ferrans VJ, Hibbs RG, Burda CD. The heart in Fabry's disease. A histochemical and electron microscopic study. Am J Cardiol 1969; 24: 95-110

- 22** Germain DP. A new phenotype of Fabry disease with intermediate severity between the classical form and the cardiac variant. *Contrib Nephrol* 2001; 136: 234-240
- 23** Hilz MJ, Brys M, Marthol H, Stemper B, Dutsch M. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. *Neurology* 2004; 62: 1066-1072
- 24** Hoffmann B, Reinhardt D, Koletzko B. Effect of enzyme-replacement therapy on gastrointestinal symptoms in Fabry disease. *Eur J Gastroenterol Hepatol* 2004; 16: 1067-1069
- 25** Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). *J Med Genet* 2005; 42: 247-252
- 26** Kallioikoski RJ, Kantola I, Kallioikoski KK. et al. The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. *J Inherit Metab Dis* 2006; 29: 112-118
- 27** Kampmann C, Wiethoff CM, Perrot A, Beck M, Dietz R, Osterziel KJ. The heart in Anderson Fabry disease. *Z Kardiol* 2002; 91: 786-795
- 28** Kampmann CRM, Böhner F, Kim KS, Bajbouj M, Beck M. Influence of enzyme replacement therapy on Anderson-Fabry disease associated hypertrophic infiltrative cardio-myopathy. *Eur J Pediatr* 2002; 161: R165
- 29** Kampmann C. Enzyme replacement therapy and the heart. Fabry disease: Perspectives from 5 years of FOS. In: Metha A, Beck M, Sunder-Plassmann G (eds) 2006, p. 257-262
- 30** Larralde M, Boggio P, Amartino H, Chamoles N. Fabry disease: a study of 6 hemizygous men and 5 heterozygous women with emphasis on dermatologic manifestations. *Arch Dermatol* 2004; 140: 1440-1446
- 31** Lidove O, Jaussaud R, Aracting S. Dermatological and soft-tissue manifestations of Fabry disease: characteristics and response to enzyme replacement therapy. In: Metha A, Beck M, Sunder-Plassmann G (eds), Eds.; Fabry disease: Perspectives from 5 years of FOS. PharmaGenesis Ltd Oxford 2006, p. 233-240
- 32** Liston EH, Levine MD, Philippart M. Psychosis in Fabry disease and treatment with phenoxybenzamine. *Arch Gen Psychiatry* 1973; 29: 402-403
- 33** Lockmann LA, D BH, Krivit W, Desnick RJ. Relief of pain of Fabry's disease by diphenylhydantoin. *Neurology* 1973; 28: 871-879
- 34** Lyon MF. X-chromosome inactivation: a repeat hypothesis. *Cytogenet Cell Genet* 1998; 80: 133-137
- 35** MacDermot K, Brown A, Jones Y, Zuckerman J. Enzyme replacement therapy reverses cardiomyopathy of Fabry disease; results of a randomized, double blind, placebo controlled trial. *Eur J Hum Gen* 2001; 9: S92
- 36** MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. *J Med Genet* 2001; 38: 769-775
- 37** MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. *J Med Genet* 2001; 38: 750-760
- 38** Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. *Jama* 1999; 281: 249-254
- 39** Mendez MF, Stanley TM, Medel NM, Li Z, Tedesco DT. The vascular dementia of Fabry's disease. *Dement Geriatr Cogn Disord* 1997; 8: 252-257
- 40** Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. *Ann Neurol* 1996; 40: 8-17
- 41** Mohrenschlager M, Ring J, Abeck D. Skin manifestations of Fabry disease. *Jama* 2001; 286: 1315
- 42** Moore DF, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T. et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. *Stroke* 2002; 33: 525-531
- 43** Müller MJ. Neuropsychiatric and psychosocial aspects of Fabry disease. Fabry disease: Perspectives from 5 years of FOS. In: Metha A, Beck M, Sunder-Plassmann G (eds) 2006, p. 281-294
- 44** O'Brien BD, Shnitka TK, McDougall RB. et al. Pathophysiologic and ultrastructural basis for intestinal symptoms in Fabry's disease. *Gastroenterology* 1982; 82: 957-962

- 45** Ramaswami U, Whybra C, Parini R. et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. *Acta Paediatr* 2006; 95: 86-92
- 46** Ries M, Ramaswami U, Parini R. et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. *Eur J Pediatr* 2003; 162: 767-772
- 47** Ries M, Gupta S, Moore DF. et al. Pediatric Fabry disease. *Pediatrics* 2005; 115: e344-355
- 48** Ries M, Clarke JT, Whybra C. et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. *Pediatrics* 2006; 118: 924-932
- 49** Rolfs A, Bottcher T, Zschiesche M. et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. *Lancet* 2005; 366: 1794-1796
- 50** Schiffmann R, Murray GJ, Treco D. et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. *Proc Natl Acad Sci USA* 2000; 97: 365-370
- 51** Schiffmann R, Moore DF. Neurological manifestations of Fabry disease. *Fabry disease: Perspectives from 5 years of FOS*. In: Metha A, Beck M, Sunder-Plassmann G (eds) 2006, p. 215-225
- 52** Schiffmann R, Kopp JB, Austin HA. et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. *JAMA* 2001; 285: 2743-2749
- 53** Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. *Nephrol Dial Transplant* 2006; 21: 345-354
- 54** Schwarting A, Dehout F, Feriozzi S, Beck M, Mehta A, Sunder-Plassmann G. Enzyme replacement therapy and renal function in 201 patients with Fabry disease. *Clin Nephrol* 2006; 66: 77-84
- 55** Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry's disease. *Arch Ophthalmol* 1979; 97: 671-676
- 56** Sheth KJ, Bernhard GC. The arthropathy of Fabry disease. *Arthritis Rheum* 1979; 22: 781-783
- 57** Sheth KJ, Roth DA, Adams MB. Early renal failure in Fabry's disease. *Am J Kidney Dis* 1983; 2: 651-654
- 58** Sodi A, Ioannidis A, Pitz S. Ophthalmological manifestations of Fabry disease. *Fabry disease: Perspectives from 5 years of FOS*. In: Metha A, Beck M, Sunder-Plassmann G (eds) 2006, p. 249-262
- 59** Spada M, Pagliardini S, Yasuda M. et al. High incidence of later-onset fabry disease revealed by newborn screening. *Am J Hum Genet* 2006; 79: 31-40
- 60** Spaeth GL, Frost P. Fabry's disease. Its ocular manifestations. *Arch Ophthalmol* 1965; 74: 760-769
- 61** Spinelli L, Pisani A, Sabbatini M. et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. *Clin Genet* 2004; 66: 158-165
- 62** Sunder-Plassmann G. Renal manifestations of Fabry disease. *Fabry disease: Perspectives from 5 years of FOS*. In: Metha A, Beck M, Sunder-Plassmann G (eds) 2006, p. 203-214
- 63** Thurberg BL, Rennke H, Colvin RB. et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. *Kidney Int* 2002; 62: 1933-1946
- 64** Weidemann F, Breunig F, Beer M. et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. *Circulation* 2003; 108: 1299-1301
- 65** Wilcox WR, Banikazemi M, Guffon N. et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. *Am J Hum Genet* 2004; 75: 65-74
- 66** Schiffmann R, Askari H, Timmons M. et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry Disease who are on longterm biweekly dosing. *J Am Soc Nephrol* 2007; 18: 1576-1583